---
schema_version: "secwatch.filing_event.v1"
accession: "0001104659-22-072157"
form_type: "8-K"
ticker: "VYNE"
cik: "0001566044"
company_name: "VYNE Therapeutics Inc."
filed_at: "2022-06-17T23:59:59+00:00"
generated_at: "2026-06-25T00:52:03.257109+00:00"
event_type: "other_material"
sentiment: "neutral"
materiality_score: 0.65
calibrated_materiality_score: 0.65
confidence: "high"
source: SEC EDGAR
---

# VYNE completes Phase 2a enrollment for FMX114; extends In4Derm Oral BETi option to Feb 2023

## Summary
- Enrollment completed in Phase 2a trial of FMX114 for mild-to-moderate atopic dermatitis; top-line results expected in 6-8 weeks.
- Option term for Oral BETi Compounds extended to Feb 28, 2023; VYNE to pay In4Derm £300,000 by June 30, 2022.
- Upon discovery of two Oral BETi Compounds with specified molecular profile, VYNE to pay In4Derm additional £850,000.
- Previous Phase 1b segment showed statistically significant reduction in ADSI score and pruritus with FMX114 vs vehicle.

## SEC filing metadata
- accession: 0001104659-22-072157
- form_type: 8-K
- ticker: VYNE
- cik: 0001566044
- company_name: VYNE Therapeutics Inc.
- filed_at: 2022-06-17T23:59:59+00:00
- event_type: other_material
- sentiment: neutral
- materiality_score: 0.65
- calibrated_materiality_score: 0.65
- confidence: high
- sec_items: 1.01, 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1566044/000110465922072157/0001104659-22-072157-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1566044/000110465922072157/tm2218445d1_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001104659-22-072157
- JSON: https://secwatch.observer/filing/0001104659-22-072157.json
- Plain text: https://secwatch.observer/filing/0001104659-22-072157.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.